[DOI] [PubMed] [Google Scholar] 14.Labbe G, Pessayre D, Fromenty B
April 1, 2026: More Than 3,500 Claims Filed in GLP-1 Litigation Over Wegovy and Other Drugs There are now 3,546 pending claims in MDL -3094 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation , which represents people alleging injuries from Wegovy and other GLP-1 drugs
Several GLP-1RAs CVOTs included patients with chronic kidney disease and showed consistent cardiovascular and some renal benefits
That same month, Hims announced it would partner with BPI on its GLP-1 drugs, producing the injectables at the very 503B facility that Rubin mentioned in the lawsuit
Legitimate peptide therapies [like a GLP-1], intended for human use, require medical oversight, and must be dispensed through licensed pharmacies
Mochida Pharmaceutical Co